Results 41 to 50 of about 11,886 (196)

Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study

BMC Nephrology, 2023
Background C3 Glomerulopathy (C3G) is a rare glomerular disease caused by dysregulation of the complement pathway. Based on its pathophysiology, treatment with the monoclonal antibody eculizumab targeting complement C5 may be a therapeutic option. Due to
Thomas Welte, Frederic Arnold, Lukas Westermann, Felix A. Rottmann, Martin J. Hug, Elke Neumann-Haefelin, Athina Ganner   +6 more
doaj   +1 more source

Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal [PDF]

, 2021
Contains fulltext : 241453.pdf (Publisher’s version ) (Open Access)BACKGROUND: The introduction of eculizumab has significantly improved the outcome of patients with atypical haemolytic uraemic syndrome (aHUS).
van der Heijden, Joost W., Heijden, J.W. van der, Kar, N.C.A.J. van de, van de Kar, Nicole C. A. J., Duineveld, Caroline, Wetzels, Jack F. M., Bouwmeester, Romy, Bouwmeester, R.N., Berger, S.P., Wetzels, J., Duineveld, C., Berger, Stefan P.   +11 more
core   +1 more source

Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy

Frontiers in Pediatrics, 2021
Background: Transplant-associated thrombotic microangiopathy (TA-TMA) is a serious complication of hematopoietic stem cell transplantation (HSCT) associated with high morbidity and mortality. High-risk TA-TMA (hrTA-TMA) is characterized by multifactorial
Laura Gomez-Ganda, Maria Isabel Benitez-Carabante, Aurora Fernandez-Polo, Marina Muñoz-Lopez, Berta Renedo-Miro, Gema Ariceta, Cristina Diaz De Heredia   +6 more
doaj   +1 more source

Eculizumab in Pediatric Dense Deposit Disease [PDF]

, 2015
Dense deposit disease (DDD), a subtype of C3 glomerulopathy, is a rare disease affecting mostly children. Treatment options are limited. Debate exists whether eculizumab, a monoclonal antibody against complement factor C5, is effective in DDD.
Bouts, Antonia H. M., Hoppe, Bernd, Roelofs, Joris J. T. H., Schriemer, Pietrik J., Florquin, Sandrine, Amann, Kerstin, Groothoff, Jaap W., Garrelfs, Mark R., van den Heuvel, L. P., Oosterveld, Michiel J. S., Davin, Jean-Claude   +10 more
core   +1 more source

Eculizumab versus rituximab in generalised myasthenia gravis [PDF]

, 2022
OBJECTIVE: Myasthenia gravis (MG) is the most common autoimmune disorder affecting the neuromuscular junction. However, evidence shaping treatment decisions, particularly for treatment-refractory cases, is sparse.
Regner-Nelke, Liesa, Arat, Ercan, Mergenthaler, Philipp, Vielhaber, Stefan, Stascheit, Frauke, Pawlitzki, Marc, Totzeck, Andreas, Nelke, Christopher, Schroeter, Christina B, Huntemann, Niklas, Öztürk, Menekse, Hagenacker, Tim, Melzer, Nico, Schreiber, Stefanie, Gassa, Asmae, Schroeter, Michael, Meisel, Andreas, Berger, Benjamin, Ruck, Tobias, Hartung, Hans-Peter, Wiendl, Heinz, Stetefeld, Henning, Meuth, Sven G   +22 more
core   +1 more source

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor, Takanobu Nadai, Kei Irie, Wen Rui Tan, Sanjana Parikh, Anhar Hosawi, Matthijs W. van Hoogdalem, Ronaldo Morales Junior, Sonya Tang Girdwood, Abbie D. Leino, Kana Mizuno, Alexander A. Vinks, Tomoyuki Mizuno   +12 more
wiley   +1 more source

Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis

Annals of Clinical and Translational Neurology
Objective Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy and tolerability for patients with anti‐acetylcholine receptor‐positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials and subsequent ...
Daiki Tokuyasu, Shigeaki Suzuki, Akiyuki Uzawa, Yuriko Nagane, Masayuki Masuda, Shingo Konno, Tomoya Kubota, Makoto Samukawa, Takamichi Sugimoto, Kei Ishizuchi, Munenori Oyama, Manato Yasuda, Hiroyuki Akamine, Yosuke Onishi, Yasushi Suzuki, Naoki Kawaguchi, Naoya Minami, Takashi Kimura, Masanori P. Takahashi, Hiroyuki Murai, Kimiaki Utsugisawa   +20 more
doaj   +1 more source

Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study

Therapeutic Advances in Neurological Disorders, 2020
Background: In the phase III eculizumab for refractory generalized myasthenia gravis REGAIN study [ClinicalTrials.gov identifier: NCT01997229] and its open-label extension (OLE) [ClinicalTrials.gov identifier: NCT02301624], patients with treatment ...
Saiju Jacob, Hiroyuki Murai, Kimiaki Utsugisawa, Richard J. Nowak, Heinz Wiendl, Kenji P. Fujita, Fanny O’Brien, James F. Howard   +7 more
doaj   +1 more source

Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network

Hematology Reports, 2023
Paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired hematologic disorder, can be treated with C5 inhibitors (C5i) such as eculizumab or ravulizumab.
Jesse Fishman, Seth Kuranz, Michael M. Yeh, Kaylen Brzozowski, Herman Chen   +4 more
doaj   +1 more source

Fatigue in Myasthenia Gravis: Recent Advances and Emerging Concepts

Muscle &Nerve, EarlyView.
ABSTRACT Fatigue is a common, often disabling symptom in myasthenia gravis (MG), distinct from muscle fatigability, and strongly associated with reduced quality of life. This narrative review examines current evidence on fatigue in MG, its patient impact, and future research directions. Earlier studies, mostly small and heterogeneous, reported a highly
Yvonne J. M. Campman, Martijn R. Tannemaat, Annabel M. Ruiter, Sarah Hoffmann   +3 more
wiley   +1 more source